Dynamic contrast-enhanced and diffusion-weighted MRI of cervical carcinoma: Correlations with Ki-67 proliferation status.

OBJECTIVES: To investigate the association of quantitative parameter (apparent diffusion coefficient [ADC]) from diffusion-weighted imaging (DWI) and various quantitative and semiquantitative parameters from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) with Ki-67 proliferation index (PI) in cervical carcinoma (CC). METHODS: A total of 102 individuals with CC who received 3.0 T MRI examination (DWI and DCE MRI) between October 2016 and December 2022 were enrolled in our investigation. Two radiologists separately assessed the ADC parameter and various quantitative and semiquantitative parameters including (volume transfer constant [Ktrans], rate constant [kep], extravascular extracellular space volume fraction [ve], volume fraction of plasma [vp], time to peak [TTP], maximum concentration [MaxCon], maximal slope [MaxSlope] and area under curve [AUC]) for each tumor. Their association with Ki-67 PI was analyzed by Spearman association analysis. The discrepancy between low-proliferation and high-proliferation groups was subsequently analyzed. The receiver operating characteristic (ROC) curve analysis utilized to identify optimal cut-off points for significant parameters. RESULTS: Both ADC (ρ = -0.457, p < 0.001) and Ktrans (ρ = -0.467, p < 0.001) indicated a strong negative association with Ki-67 PI. Ki-67 PI showed positive correlations with TTP, MaxCon, MaxSlope and AUC (ρ = 0.202, 0.231, 0.309, 0.235, respectively; all p values<0.05). Compared with the low-proliferation group, high-Ki-67 group presented a significantly lower ADC (0.869 ± 0.125 × 10-3 mm2/s vs. 1.149 ± 0.318 × 10-3 mm2/s; p < 0.001) and Ktrans (1.314 ± 1.162 min-1vs. 0.391 ± 0.390 min-1; p < 0.001), also significantly higher MaxCon values (0.756 ± 0.959 vs. 0.422 ± 0.341; p < 0.05) and AUC values (2.373 ± 3.012 vs. 1.273 ± 1.000; p < 0.05). The cut-offs of ADC, Ktrans, MaxCon and AUC for discrimating low- and high-Ki-67 groups were 0.920 × 10-3 mm2/s, 0.304 min-1, 0.209 and 1.918, respectively. CONCLUSIONS: ADC, Ktrans, TTP, MaxCon, MaxSlope and AUC are associated with Ki-67 PI. ADC and Ktrans exhibited high performance to discriminate low and high Ki-67 status of CC.

Texture analysis of apparent diffusion coefficient maps: can it identify nonresponse to neoadjuvant chemotherapy for additional radiation therapy in rectal cancer patients?

Background: Neoadjuvant chemotherapy (NCT) alone can achieve comparable treatment outcomes to chemoradiotherapy in locally advanced rectal cancer (LARC) patients. This study aimed to investigate the value of texture analysis (TA) in apparent diffusion coefficient (ADC) maps for identifying non-responders to NCT. Methods: This retrospective study included patients with LARC after NCT, and they were categorized into nonresponse group (pTRG 3) and response group (pTRG 0-2) based on pathological tumor regression grade (pTRG). Predictive texture features were extracted from pre- and post-treatment ADC maps to construct a TA model using RandomForest. The ADC model was developed by manually measuring pre- and post-treatment ADC values and calculating their changes. Simultaneously, subjective evaluations based on magnetic resonance imaging assessment of TRG were performed by two experienced radiologists. Model performance was compared using the area under the curve (AUC) and DeLong test. Results: A total of 299 patients from two centers were divided into three cohorts: the primary cohort (center A; n = 194, with 36 non-responders and 158 responders), the internal validation cohort (center A; n = 49, with 9 non-responders) and external validation cohort (center B; n = 56, with 33 non-responders). The TA model was constructed by post_mean, mean_change, post_skewness, post_entropy, and entropy_change, which outperformed both the ADC model and subjective evaluations with an impressive AUC of 0.997 (95% confidence interval [CI], 0.975-1.000) in the primary cohort. Robust performances were observed in internal and external validation cohorts, with AUCs of 0.919 (95% CI, 0.805-0.978) and 0.938 (95% CI, 0.840-0.985), respectively. Conclusions: The TA model has the potential to serve as an imaging biomarker for identifying nonresponse to NCT in LARC patients, providing a valuable reference for these patients considering additional radiation therapy.

Additive value of exposure parameters for breast cancer diagnosis in digital mammography.

OBJECTIVES: To investigate the effect of different breast lesions on exposure parameters in digital mammography and to determine whether the exposure parameters can additively improve diagnostic efficiency. METHODS: Craniocaudal view and mediolateral view full-field digital mammography images from 982 women with unilateral lesions (341 with malignant lesions, 189 with benign lesions, and 452 healthy women) obtained at Nanfang Hospital were reviewed. Differences in exposure parameters (tube voltage and load, breast thickness (BT), and average glandular dose (AGD)) between breasts were calculated. The relationships between parameter differences and lesion size were explored. A logistic regression model was used based on the AGD and BT differences, and the area under the receiver operating characteristic curve (AUC) was used to assess the performance of these parameters in differentiating malignant from benign and healthy subjects. Independently, data from 129 women (82 with malignant and 47 with benign lesions) treated at Sun Yat-sen Memorial Hospital were collected to validate the model. RESULTS: Differences in tube voltage and load, BT, and AGD between breasts were significantly greater in the malignant subjects than benign (p < 0.05) and healthy subjects (p < 0.05). The AUCs for the comparisons of malignant vs. healthy subjects, malignant vs. benign subjects, and benign vs. healthy subjects were 0.77 ± 0.02, 0.72 ± 0.02, and 0.57 ± 0.02, respectively. The model combining the exposure parameters with the BI-RADS category resulted in a higher AUC (0.910 ± 0.03) compared with physician diagnosis alone (0.820 ± 0.04) for differentiating between malignant and benign lesions. CONCLUSIONS: Exposure parameters additively improved diagnostic accuracy for breast cancer and yielded more reliable results. KEY POINTS: • Differences in kVp, mAs, BT, and AGD between breasts were significantly greater in the malignant subjects than benign and healthy subjects. • The model combining exposure parameters with the BI-RADS category resulted in a higher AUC compared with the physician's diagnosis for differentiating between malignant and benign lesions. • Exposure parameters additively improved diagnostic accuracy for breast cancer.

Radiomics-Based Preoperative Prediction of Lymph Node Status Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

Background and Purpose: Lymph node status is a key factor for the recommendation of organ preservation for patients with locally advanced rectal cancer (LARC) following neoadjuvant therapy but generally confirmed post-operation. This study aimed to preoperatively predict the lymph node status following neoadjuvant therapy using multiparametric magnetic resonance imaging (MRI)-based radiomic signature. Materials and Methods: A total of 391 patients with LARC who underwent neoadjuvant therapy and TME were included, of which 261 and 130 patients were allocated to the primary cohort and the validation cohort, respectively. The tumor area, as determined by preoperative MRI, underwent radiomics analysis to build a radiomic signature related to lymph node status. Two radiologists reassessed the lymph node status on MRI. The radiomic signature and restaging results were included in a multivariate analysis to build a combined model for predicting the lymph node status. Stratified analyses were performed to test the predictive ability of the combined model in patients with post-therapeutic MRI T1-2 or T3-4 tumors, respectively. Results: The combined model was built in the primary cohort, and predicted lymph node metastasis (LNM+) with an area under the curve of 0.818 and a negative predictive value (NPV) of 93.7% were considered in the validation cohort. Stratified analyses indicated that the combined model could predict LNM+ with a NPV of 100 and 87.8% in the post-therapeutic MRI T1-2 and T3-4 subgroups, respectively. Conclusion: This study reveals the potential of radiomics as a predictor of lymph node status for patients with LARC following neoadjuvant therapy, especially for those with post-therapeutic MRI T1-2 tumors.

Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

OBJECTIVE: The aim of this study was to investigate whether pretherapeutic, multiparametric magnetic resonance imaging (MRI) radiomic features can be used for predicting non-response to neoadjuvant therapy in patients with locally advanced rectal cancer (LARC). METHODS: We retrospectively enrolled 425 patients with LARC [allocated in a 3:1 ratio to a primary (n = 318) or validation (n = 107) cohort] who received neoadjuvant therapy before surgery. All patients underwent T1-weighted, T2-weighted, diffusion-weighted, and contrast-enhanced T1-weighted MRI scans before receiving neoadjuvant therapy. We extracted 2424 radiomic features from the pretherapeutic, multiparametric MR images of each patient. The Wilcoxon rank-sum test, Spearman correlation analysis, and least absolute shrinkage and selection operator regression were successively performed for feature selection, whereupon a multiparametric MRI-based radiomic model was established by means of multivariate logistic regression analysis. This feature selection and multivariate logistic regression analysis was also performed on all single-modality MRI data to establish four single-modality radiomic models. The performance of the five radiomic models was evaluated by receiver operating characteristic (ROC) curve analysis in both cohorts. RESULTS: The multiparametric, MRI-based radiomic model based on 16 features showed good predictive performance in both the primary (p < 0.01) and validation (p < 0.05) cohorts, and performed better than all single-modality models. The area under the ROC curve of this multiparametric MRI-based radiomic model achieved a score of 0.822 (95% CI 0.752-0.891). CONCLUSIONS: We demonstrated that pretherapeutic, multiparametric MRI radiomic features have potential in predicting non-response to neoadjuvant therapy in patients with LARC.

Bioinformatic gene analysis for potential biomarkers and therapeutic targets of atrial fibrillation-related stroke.

BACKGROUND: Atrial fibrillation (AF) is one of the most prevalent sustained arrhythmias, however, epidemiological data may understate its actual prevalence. Meanwhile, AF is considered to be a major cause of ischemic strokes due to irregular heart-rhythm, coexisting chronic vascular inflammation, and renal insufficiency, and blood stasis. We studied co-expressed genes to understand relationships between atrial fibrillation (AF) and stroke and reveal potential biomarkers and therapeutic targets of AF-related stroke. METHODS: AF-and stroke-related differentially expressed genes (DEGs) were identified via bioinformatic analysis Gene Expression Omnibus (GEO) datasets GSE79768 and GSE58294, respectively. Subsequently, extensive target prediction and network analyses methods were used to assess protein-protein interaction (PPI) networks, Gene Ontology (GO) terms and pathway enrichment for DEGs, and co-expressed DEGs coupled with corresponding predicted miRNAs involved in AF and stroke were assessed as well. RESULTS: We identified 489, 265, 518, and 592 DEGs in left atrial specimens and cardioembolic stroke blood samples at < 3, 5, and 24 h, respectively. LRRK2, CALM1, CXCR4, TLR4, CTNNB1, and CXCR2 may be implicated in AF and the hub-genes of CD19, FGF9, SOX9, GNGT1, and NOG may be associated with stroke. Finally, co-expressed DEGs of ZNF566, PDZK1IP1, ZFHX3, and PITX2 coupled with corresponding predicted miRNAs, especially miR-27a-3p, miR-27b-3p, and miR-494-3p may be significantly associated with AF-related stroke. CONCLUSION: AF and stroke are related and ZNF566, PDZK1IP1, ZFHX3, and PITX2 genes are significantly associated with novel biomarkers involved in AF-related stroke.